Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)

EKİCİ, BERKAY; Yaman, Mehmet; KÜÇÜK, MURATHAN; Dereli, Seckin; Yenercag, Mustafa; Yigit, Zerrin; Bas, Mehmet; KARAVELİOĞLU, YUSUF; Cakmak, Huseyin; Kivrak, Tarik; Ozkan, Hakan; Altin, Cihan; Sabanoglu, Cengiz; Demirkan, Burcu; Atas, Ali; Kilicaslan, Fethi; Altay, Hakan; Tengiz, Istemihan; Erkan, Aycan; Kilicaslan, Baris; Olgun, Fatih; Durakoglugil, Murtaza; ALHAN, ASLIHAN; ZOGHİ, MEHDİ

doi:10.5543/tkda.2021.63099

Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)

EKİCİ B., Yaman M., KÜÇÜK M., Dereli S., Yenercag M., Yigit Z., ...More

TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, vol.49, no.5, pp.357-368, 2021 (ESCI, Scopus, TRDizin)

Publication Type: Article / Article
Volume: 49 Issue: 5
Publication Date: 2021
Doi Number: 10.5543/tkda.2021.63099
Journal Name: TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY
Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Central & Eastern European Academic Source (CEEAS), EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
Page Numbers: pp.357-368
Keywords: Angiotensin receptor neprilysin inhibitor, heart failure with reduced ejection fraction, sacubitril, valsartan, real-world, SACUBITRIL/VALSARTAN IMPROVES, ENALAPRIL, DISEASE
Akdeniz University Affiliated: Yes

Abstract

Objective: Heart failure (HF) is a growing public health problem with high morbidity and mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a promising treatment for HF with reduced ejection fraction (HFrEF). Here, we shared our experience with the use of ARNi in HFrEF from multiple centers in Turkey.